Clinical and pathological study of neoadjuvant chemotherapy with paclitaxel liposome in bulky cervical cancer

OBJECTIVE:To compare the efficacy and toxicity of paclitaxel liposome and traditional paclitaxel injection in the bulky cervical cancer.METHODS:Totally 55 patients with comparable bulky cervical cancer were randomized into experimental group and control group.The experimental group including 35 patients received paclitaxel liposome 135 mg/m2 each cycle,and the control group including 20 patients received paclitaxel 135 mg/m2 each cycle.Both groups combined with carboplatin per cycle every 3 weeks.The efficacy and safety were evaluated after two cycles,and before surgery.Postoperative pathological analysis and comparison of toxicity were made.RESULTS: The local total effective rate was 85.7% in the experimental group and 55.0% in the control group.The difference was statistically significant(P0.05).Pathologic lymph node metastasis occurred in 1 patient in the experimental group(2.9%),while in 5 cases in control group(25.0%).The difference was statistically significant(P0.05).The better of the local effect demonstrated more significant pathological response(χ2=54.76,P0.05).The hematologic toxicity showed no significant difference between two groups,while non-hematologic toxicity,such as the incidence of skin rash and peripheral neuritis,was significantly lower in experimental group than that in the control group.The difference was significant(P0.05).CONCLUSIONS: Neoadjuvant chemotherapy with paclitaxel liposome and Carboplatin improves local efficacy and pathological response,creats the opportunity of surgery of the patient with locally advanced cervical cancer.The toxicity of paclitaxel liposome is significantly lower than that of paclitaxel and the clinical application is safe and reliable.